FIELD: biotechnology.
SUBSTANCE: present invention refers to biotechnology. There are presented antibodies and their antigen-binding fragments against IL-1-beta. Besides, coding nucleic acid, a vector, a host cell and methods for producing the antibody and its antigen-binding fragment are described. Also provided are a pharmaceutical composition and a method of treating a disease associated with IL-1 beta; a kit and a method of detecting presence of IL-1 beta in a biological sample.
EFFECT: present invention can be used in treating and diagnosing various inflammatory diseases.
45 cl, 6 dwg, 7 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF USE OF ANTIBODIES AGAINST HLA-G | 2019 |
|
RU2810326C2 |
| ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE | 2016 |
|
RU2815681C1 |
| COMBINATION THERAPY OF ANTIBODY TO PROGASTRIN AND IMMUNOTHERAPY FOR CANCER TREATMENT | 2018 |
|
RU2784604C2 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| BISPECIFIC ANTIBODIES BINDING TO TFR | 2019 |
|
RU2810756C2 |
| DRUG CONJUGATES FROM MONOCLONAL CMET BINDING AGENTS AND THEIR USE | 2019 |
|
RU2813828C2 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
